As the old saying goes, strike when the iron is hot. That's what a new gene editing start-up named Beam Therapeutics hopes to do by conducting an initial public offering (IPO) less than two years after forming and more than a year before it asks regulators for permission to begin clinical trials. Given the excitement over genetic medicines, it might be wise to take advantage of the open window now.
Assuming the IPO proceeds as planned, Beam Therapeutics will offer investors a second chance to own a next-generation gene editing technology platform and the first next-generation CRISPR tool. Here's why investors might want to keep the business on their radar.
Image source: Getty Images.
Beam Therapeutics bears some similarities to Editas Medicine (NASDAQ:EDIT). Both trace their origins back to the Broad Institute in Boston. They share a trio of all-star scientific founders: Dr. Feng Zhang, Dr. David Liu, and Dr. Keith Joung. Each company's technology platform is built on CRISPR-based tools.
But the differences are more important for investors. Editas Medicine is developing gene editing tools that require Cas enzymes to cut both strands of DNA. While that theoretically provides the ability to delete or insert genetic sequences to treat diseases, the approach relies on innate DNA repair mechanisms. When the built-in safeguards on those mechanisms break down, cells can turn cancerous. CRISPR-CasX tools can also create unintended genetic edits, and have a relatively low efficiency.
Beam Therapeutics is developing gene editing tools based on a new technique called base editing. The enzymatic approach doesn't make double-stranded breaks in DNA. Instead, it induces chemical reactions to change the sequence of the genetic alphabet -- A (adenine), T (thymine), C (cytosine), and G (guanine) -- one letter at a time. Base editing can make A-to-G edits, C-to-T edits, G-to-A edits, and T-to-C edits.
The next-generation approach decouples CRISPR gene editing tools and the need to make double-stranded breaks in DNA, which is the most pressing concern facing Editas Medicine, CRISPR Therapeutics (NASDAQ:CRSP), and Intellia Therapeutics (NASDAQ:NTLA).
CRISPR-CasX Gene Editing
CRISPR Base Editing
Does it cut DNA?
Yes, enzymatically cuts both strands of DNA
Can be used to insert new genetic material into a sequence?
No, but it can enzymatically change an existing DNA sequence
Does it trigger DNA repair mechanisms?
Source: Beam Therapeutics, author.
While base editing can't make every possible edit (example: A-to-T edits), it can target a number of disease-driving genetic errors. And Beam Therapeutics has inked important collaboration deals to augment the capabilities of its technology platform:
After reviewing the details, investors see that there's a tangled web of related transactions that all flow back to the Broad Institute, which is going to great lengths to extract every ounce of value from its scientific discoveries. Similar actions have caused a stir in the scientific community in recent years. If the profit-seeking terms of the non-profit research institution's agreements are too strict, then it may pose a risk to Beam Therapeutics at the expense of investors.
Image source: Getty Images.
Investors familiar with gene editing stocks will immediately recognize the programs included in the pipeline of the base editing pioneer. The lead assets take aim at blood disorders, and are part of a push to engineer better immunotherapies to treat cancer.
In beta thalassemia and sickle cell disease, Beam Therapeutics is first attempting to increase the production of fetal hemoglobin, which confers natural immunity to both conditions. That's similar to the lead drug candidate of CRISPR Therapeutics, which recently demonstrated promising results from the first two patients in a phase 1 clinical trial.
A second program in sickle cell disease aims to directly correct the genetic mutation responsible for the blood disorder. It involves changing a single base -- perfectly suited for base editing.
In immunotherapy, Beam Therapeutics is working to engineer better chimeric antigen receptor T (CAR-T) cells that can be used as cellular medicines to treat various types of cancers. CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics are deploying CRISPR gene editing in the same applications, while Precision BioSciences (NASDAQ:DTIL) is leaning on ARCUS gene editing to do the same. The latter's lead drug candidates are in immunotherapy, a unique distinction among gene editing stocks.
Beam Therapeutics' pipeline also includes a range of potential assets aimed at gene correction, gene silencing, and more complex editing, but none have entered clinical trials. The company doesn't expect to file investigational new drug (IND) applications -- required for regulators to sign off on the start of clinical trials -- until 2021. But since the window for an IPO might be slammed shut by then, the business is exploring a market debut now.
There aren't many details in the company's S1 filing concerning a potential date for a market debut or how much money the company is aiming to raise. The filing says $100 million, but that's just a placeholder for the initial submission. The actual amount will be determined once Wall Street gets an idea of the level of interest in an IPO, which will determine the number of shares to offer and the price.
Assuming the IPO takes place, Beam Therapeutics and base editing offer investors a technological upgrade over the first-generation gene editing platforms leaning on CRISPR-CasX tools. The next-generation tools aren't perfect, and there are risks related to the agreements with the Broad Institute and sister start-ups, but this is certainly a gene editing stock worth watching.
Read the original here:
- Medical genetics - Wikipedia - January 10th, 2020
- Genetic Medicine | Department of Medicine - January 10th, 2020
- Distribution of Genes Encoding Virulence Factors and the Genetic Diver | IDR - Dove Medical Press - January 10th, 2020
- In defence of imprecise medicine: the benefits of routine treatments for common diseases - The Conversation UK - January 10th, 2020
- IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease... - January 10th, 2020
- Study ties gene active in developing brain to autism - Spectrum - January 10th, 2020
- Faculty and alumni appointed to state medical boards - The South End - January 10th, 2020
- Why This Thematic Healthcare Could be a January Winner - ETF Trends - January 10th, 2020
- New year health kicks are great but your environment is also vital - The Guardian - January 10th, 2020
- Biofidelity and Agilent complete successful molecular assay study for rapid and accurate detection of key lung cancer mutations - BioSpace - January 10th, 2020
- New MD Treatments the Main Goal of Astellas, Audentes Merger - Muscular Dystrophy News - January 10th, 2020
- Physicians' Education Resource Presents the 2nd Annual Precision Medicine Symposium in New York City - BioSpace - January 10th, 2020
- A Genetic Mutation Is Responsible for Mysterious Deaths in the Amish Community, Researchers Say - Gizmodo - January 10th, 2020
- Kyoto Univ.-distributed iPS cells found with abnormalities after differentiation - The Mainichi - January 10th, 2020
- The Importance of Understanding TargetProtein Interactions in Drug Discovery - Technology Networks - January 10th, 2020
- Webinar: How Providers are Harnessing the Power of Genomics to Improve Community Health - ModernHealthcare.com - January 5th, 2020
- Genomics and Medicine | NHGRI - January 5th, 2020
- These 2 Stocks Will Fall After the New Year - Motley Fool - January 5th, 2020
- Free Gene Therapy Available for Patients with Alzheimer's - HealthITAnalytics.com - January 5th, 2020
- Chinese Researcher Who Created Gene-Edited Babies Sentenced To 3 Years In Prison - NPR - January 5th, 2020
- Duke Researchers Garner Over $6 Million in NIH Funding to Fight Genetic Diseases - Duke Today - January 5th, 2020
- Stanford Team Proposes Automated Clinical Trial Accrual Strategy, Increased Trial Annotation - Precision Oncology News - January 5th, 2020
- Dr. Timothy Eberlein and Alvin Siteman named Citizens of the Year 2019 - STLtoday.com - January 5th, 2020
- Did Cellectis Just Provide a Glimpse of the Future of Cellular Medicine? - The Motley Fool - December 27th, 2019
- Sickle Cell Therapy With CRISPR Gene Editing Shows Promise : Shots - Health News - NPR - December 27th, 2019
- Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy... - December 27th, 2019
- What is multifocal pneumonia, the illness ESPN reporter Edward Aschoff tweeted about before his death? - USA TODAY - December 27th, 2019
- The travellers within us - Myanmar Times - December 27th, 2019
- How to bring precision medicine into the doctor's office - World Economic Forum - December 19th, 2019
- Form of severe malnutrition linked to DNA modification - Baylor College of Medicine News - December 19th, 2019
- 'Polygenic' profile could better predict disease risk for those with cancer mutations - Science Magazine - December 19th, 2019
- Here's Why You Should Avoid Betting on RPC (RES) Stock Now - Nasdaq - December 19th, 2019
- UNC Police Investigating Series of Credit Card Thefts on South Campus - Chapelboro.com - December 19th, 2019
- Personalized CF Medicine to be Tested for Rare Genetic Defects in Europe - Cystic Fibrosis News Today - December 19th, 2019
- Has Innovative Industrial Properties (IIPR) Outpaced Other Finance Stocks This Year? - Nasdaq - December 19th, 2019
- BioReference Laboratories Showcases 2019 Growth through the Addition of Cutting Edge Tests, Greater Access to Services, and Optimized Patient... - December 19th, 2019
- Gene Therapy Arrives - Scientific American - December 18th, 2019
- Detection of Secondary Metabolites as Biomarkers for the Early Diagnos | DMSO - Dove Medical Press - December 18th, 2019
- Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy - GlobeNewswire - December 18th, 2019
- 10 Years Ago, DNA Tests Were The Future Of Medicine. Now Theyre A Social Network And A Data Privacy Mess. - BuzzFeed News - December 18th, 2019
- Mosaic Angelman Should Be in Differential Diagnosis of AS, Study Says - Angelman Syndrome News - December 18th, 2019
- Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing - Yahoo Finance - December 18th, 2019
- Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders -... - December 18th, 2019
- Genetic clues of TB spread between cows and badgers revealed - Irish Times - December 18th, 2019
- The first U.S. trials in people put CRISPR to the test in 2019 - Science News - December 18th, 2019
- Care Coordination and Precision Medicine Improve Early Diagnoses - HealthPayerIntelligence.com - December 13th, 2019
- Penn Team Finds Genetic Variant Largely Found in Patients of African Descent that Increases Heart Failure Risk - Clinical OMICs News - December 13th, 2019
- For Nobel laureates, a whirlwind welcome - The Hub at Johns Hopkins - December 13th, 2019
- A Nobel journey a lifetime in the making - The Hub at Johns Hopkins - December 13th, 2019
- Teams of Microbes Are at Work in Our Bodies. Drexel Researchers Have Figured Out What They're up to. - DrexelNow - Drexel Now - December 13th, 2019
- 5 things a Nobel Prize winner wants you to know about science - Futurity: Research News - December 13th, 2019
- Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease - P&T... - December 13th, 2019
- Researchers unfold genetic code that controls cell function and disease - BSA bureau - December 13th, 2019
- Cannadabis: tissue culture and the future of cannabis cultivation - Health Europa - December 13th, 2019
- The genetic mutation behind a new autoinflammatory disease - Pursuit - December 13th, 2019
- 21st century medicine helps Amish deal with rare, inherited illnesses - University of Wisconsin-Madison - October 19th, 2019
- Research presented by Invitae at the American Society of Human Genetics Meeting Pushes Science and Practice of Genetics Forward - P&T Community - October 19th, 2019
- Genetic Tests For Psychiatric Drugs Now Covered By Some Insurers : Shots - Health News - NPR - October 19th, 2019
- How Artifical Intelligence Is Advancing Precision Medicine - Forbes - October 19th, 2019
- Ochsner Health System teaming up with Color on population health pilot - FierceHealthcare - October 19th, 2019
- Scientists at Wake Forest School of Medicine Identify Genetic Variation Linked to Severity of ALS - Newswise - October 19th, 2019
- 100 Health Summit: How to Make Research Better | Time.com - TIME - October 19th, 2019
- Genetic counselors save health care dollars when involved in the testing process | TheHill - The Hill - October 19th, 2019
- New Gene Therapy Approach Reduces Cost and Improves Efficiency - DocWire News - October 19th, 2019
- NIH funds new All of Us Research Program genome center to test advanced sequencing tools - National Institutes of Health - October 19th, 2019
- Gait and Aging; Statin Use in Kids: It's PodMed Double T! - MedPage Today - October 19th, 2019
- SIDS May Be Linked To A Genetic Inability To Digest Milk, Study Finds - Moms - October 19th, 2019
- Are Pricey Fertility Treatments Helping Women Have Babies...Or Preying On Them? - Women's Health - October 19th, 2019
- My Daughter and I Were Diagnosed With Autism on the Same Day - NYT Parenting - October 19th, 2019
- Embodied: The Elusive Science Of Sleep - WUNC - October 19th, 2019
- Cryptocurrency News: This Week on Bitfinex, Tether, Coinbase, & More - May 25th, 2019
- Ripple Price Forecast: XRP vs SWIFT, SEC Updates, and More - May 25th, 2019
- Cryptocurrency News: Bitcoin ETFs, Andreessen Horowitz, and Contradictions in Crypto - May 25th, 2019
- Cryptocurrency News: Looking Past the Bithumb Crypto Hack - May 25th, 2019
- Cryptocurrency News: XRP Validators, Malta, and Practical Tokens - May 25th, 2019
- Cryptocurrency News: Bitcoin ETF Rejection, AMD Microchip Sales, and Hedge Funds - May 25th, 2019
- Cryptocurrency News: What You Need to Know This Week - May 25th, 2019
- Cryptocurrency News: New Exchanges Could Boost Crypto Liquidity - May 25th, 2019
- Cryptocurrency News: Vitalik Buterin Doesn’t Care About Bitcoin ETFs - May 25th, 2019
- Bitcoin Rise: Is the Recent Bitcoin Price Surge a Sign of Things to Come or Another Misdirection? - May 25th, 2019